APH-1501
Opioid Use Disorder (CBD + LDN Nanotherapy)
Pre-clinicalActive
Key Facts
About Aphios
Aphios is a privately held, pre-revenue biotech founded in 1999 with a portfolio anchored by 87 patents and $50M in funding. Its strategy combines developing proprietary nanotherapeutics for large markets (e.g., cannabinoids for pain, ginger extract for nausea) with licensing its enabling technology platforms for drug delivery, manufacturing, and pathogen safety. The company structures development through focused LLCs/SPVs, targeting multi-billion dollar opportunities in chronic disease management and biologics safety.
View full company profile